How big is Prelude Therapeutics, Inc.?

As of Jun 18, Prelude Therapeutics, Inc. has a market capitalization of 52.37 million, with net sales of 7.00 million and a net profit of -127.83 million over the latest four quarters. The company reported shareholder's funds of 131.46 million and total assets of 175.51 million as of Dec 24.

Market Cap: As of Jun 18, Prelude Therapeutics, Inc. has a market capitalization of 52.37 million, categorizing it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, Prelude Therapeutics, Inc. reported net sales of 7.00 million and a net profit of -127.83 million.<BR><BR>Balance Sheet Snapshot: As of Dec 24, the company reported shareholder's funds of 131.46 million and total assets of 175.51 million.

What does Prelude Therapeutics, Inc. do?

Prelude Therapeutics, Inc. is a clinical-stage precision oncology company focused on developing small molecule therapies for cancer. It has a market cap of $52.37 million and reported a net profit loss of $32 million as of March 2025.

Overview:<BR>Prelude Therapeutics, Inc. is a clinical-stage precision oncology company focused on discovering and developing small molecule therapies optimized to target key driver mechanisms in cancers, operating within the Pharmaceuticals & Biotechnology industry and classified as a micro-cap company.<BR><BR>Financial Snapshot:<BR>Most recent Net Profit: -32 Million (Quarterly Results - Mar 2025)<BR>Market cap: USD 52.37 Million (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: NA (Loss Making)<BR>Industry P/E: NA<BR>Dividend Yield: 0.00%<BR>Debt Equity: -0.93<BR>Return on Equity: -123.89%<BR>Price to Book: 0.51<BR><BR>Contact Details:<BR>Address: 200 Powder Mill Road, WILMINGTON DE: 19803<BR>Tel: 1 302 4671280<BR>Website: https://preludetx.com/

Should I buy, sell or hold Prelude Therapeutics, Inc.?

Who are in the management team of Prelude Therapeutics, Inc.?

As of March 2022, the management team of Prelude Therapeutics, Inc. is led by Mr. Kris Vaddi, who is the Chief Executive Officer, Founder, and Director.

As of March 2022, the management team of Prelude Therapeutics, Inc. includes Mr. Kris Vaddi, who serves as the Chief Executive Officer, Founder, and Director.

Is Prelude Therapeutics, Inc. overvalued or undervalued?

As of November 6, 2024, Prelude Therapeutics, Inc. is considered risky and overvalued due to negative financial metrics, including a Price to Book Value of 0.56 and significant declines in stock performance compared to the S&P 500.

As of 6 November 2024, Prelude Therapeutics, Inc. has moved from a grade of does not qualify to risky. The company appears to be overvalued given its negative financial metrics and valuation ratios. The Price to Book Value stands at 0.56, the EV to EBIT is at 0.27, and the EV to EBITDA is at 0.28, indicating significant challenges in profitability and valuation relative to its assets.<BR><BR>In comparison to its peers, Prelude Therapeutics has a less favorable position; for instance, TriSalus Life Sciences, Inc. has a P/E ratio of -6.9780 and an EV to EBITDA of -8.5259, while Seer, Inc. has an EV to EBITDA of 1.1233. Prelude's negative returns are stark, with a year-to-date decline of -20.78% compared to the S&P 500's gain of 12.22%, and a one-year return of -58.61% against the S&P 500's 17.14%. These figures further reinforce the notion that the stock is overvalued in its current state.

Is Prelude Therapeutics, Inc. technically bullish or bearish?

As of September 8, 2025, Prelude Therapeutics, Inc. shows a mildly bullish trend supported by positive MACD and moving averages, despite mixed signals from Bollinger Bands and underperformance compared to the S&P 500.

As of 8 September 2025, the technical trend for Prelude Therapeutics, Inc. has changed from sideways to mildly bullish. The weekly MACD and KST indicators are both mildly bullish, while the monthly MACD is also mildly bullish, supporting a positive outlook. The daily moving averages are bullish, further reinforcing this stance. However, the monthly Bollinger Bands and KST are bearish, indicating some caution. The RSI shows a bullish signal on a monthly basis but no signal on the weekly. Overall, the indicators suggest a mildly bullish stance, albeit with some mixed signals.<BR><BR>In terms of performance, the stock has underperformed significantly compared to the S&P 500 across multiple periods, with a YTD return of -20.78% versus the S&P 500's 12.22%, and a 1Y return of -58.61% compared to 17.14% for the index.